Recital 3, Regulation (EU) 2026/1826

In forcesince 28 Jul 2026

Commission Directive 2004/58/EC [Commission Directive 2004/58/EC of 23 April 2004 amending Council Directive 91/414/EEC to include alpha-cypermethrin, benalaxyl, bromoxynil, desmedipham, ioxynil and phenmedipham as active substances (OJ L 120, 24.4.2004, p. 26, ELI: http://data.europa.eu/eli/dir/2004/58/oj).] included phenmedipham in Annex I to Directive 91/414/EEC as an active substance until 28 February 2015 and it was subsequently included in Part A of the Annex to Implementing Regulation (EU) No 540/2011. The approval of phenmedipham was extended nine times, most recently by Commission Implementing Regulation (EU) 2025/99 [Commission Implementing Regulation (EU) 2025/99 of 21 January 2025 amending Implementing Regulation (EU) No 540/2011 as regards the extension of the approval periods of the active substances Aureobasidium pullulans (strains DSM 14940 and DSM 14941), Bacillus amyloliquefaciens subsp. plantarum D747, benalaxyl-M, cyprodinil, dichlorprop-P, formetanate, fosetyl, halosulfuron-methyl, imazamox, milbemectin, phenmedipham, pirimicarb, Pseudomonas sp. strain DSMZ 13134, pyrimethanil, pyriofenone, pyroxsulam, spinosad, sulphur, Trichoderma harzianum Rifai strains T-22 and ITEM 908, Trichoderma asperellum (formerly T. harzianum) strains ICC012, T-25 and TV-1, Trichoderma atroviride (formerly T. harzianum) strain T11, Trichoderma gamsii (formerly T. viride) strain ICC080, triticonazole and ziram (OJ L, 2025/99, 22.1.2025, ELI: http://data.europa.eu/eli/reg_impl/2025/99/oj).] until 30 September 2026.